<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Peptidream Inc. — News on 6ix</title>
    <link>https://6ix.com/company/peptidream-inc</link>
    <description>Latest news and press releases for Peptidream Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 12:40:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/peptidream-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6220abeedb30cb6fc2fcf.webp</url>
      <title>Peptidream Inc.</title>
      <link>https://6ix.com/company/peptidream-inc</link>
    </image>
    <item>
      <title>PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner</title>
      <link>https://6ix.com/company/peptidream-inc/news/peptidream-announces-the-initiation-of-phase-1-clinical-trial-by-its-collaboration-partner</link>
      <guid isPermaLink="true">https://6ix.com/company/peptidream-inc/news/peptidream-announces-the-initiation-of-phase-1-clinical-trial-by-its-collaboration-partner</guid>
      <pubDate>Mon, 20 Apr 2026 12:40:00 GMT</pubDate>
      <description>KAWASAKI, Japan, April 20, 2026--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter &quot;PeptiDream&quot;) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Daisuke Okajima, hereinafter &quot;Asahi Kasei Therapeutics&quot;), its collaboration partner, has initiated a Phase 1 clinical trial*1 of &quot;AK1940&quot;, a selective inhibitor of TNF receptor 1 (&quot;TNFR1&quot;).</description>
    </item>
    <item>
      <title>PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues</title>
      <link>https://6ix.com/company/peptidream-inc/news/peptidream-and-alnylam-announce-achievement-of-key-milestone-in-sirna-conjugate-discovery-collaboration-demonstrating-peptide-ligand-mediated-targeted-sirna-delivery-to-specific-extrahepatic-tissues-1</link>
      <guid isPermaLink="true">https://6ix.com/company/peptidream-inc/news/peptidream-and-alnylam-announce-achievement-of-key-milestone-in-sirna-conjugate-discovery-collaboration-demonstrating-peptide-ligand-mediated-targeted-sirna-delivery-to-specific-extrahepatic-tissues-1</guid>
      <pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
      <description>KAWASAKI, Japan, December 18, 2025--A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of PeptiDream and Alnylam from 2021.</description>
    </item>
    <item>
      <title>PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis</title>
      <link>https://6ix.com/company/peptidream-inc/news/peptidream-announces-promising-pre-clinical-results-of-proprietary-oral-il-17a-and-il-17f-dual-inhibitor-with-biologic-like-efficacy-for-the-treatment-of-psoriasis</link>
      <guid isPermaLink="true">https://6ix.com/company/peptidream-inc/news/peptidream-announces-promising-pre-clinical-results-of-proprietary-oral-il-17a-and-il-17f-dual-inhibitor-with-biologic-like-efficacy-for-the-treatment-of-psoriasis</guid>
      <pubDate>Wed, 17 Dec 2025 13:00:00 GMT</pubDate>
      <description>KAWASAKI, Japan, December 17, 2025--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.</description>
    </item>
    <item>
      <title>PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&amp;T for Prostate Cancer in Japan</title>
      <link>https://6ix.com/company/peptidream-inc/news/peptidream-pdradiopharma-and-curium-group-enroll-first-patient-to-registrational-clinical-trial-of-64cu-psma-iandt-for-prostate-cancer-in-japan</link>
      <guid isPermaLink="true">https://6ix.com/company/peptidream-inc/news/peptidream-pdradiopharma-and-curium-group-enroll-first-patient-to-registrational-clinical-trial-of-64cu-psma-iandt-for-prostate-cancer-in-japan</guid>
      <pubDate>Wed, 15 Oct 2025 12:50:00 GMT</pubDate>
      <description>KAWASAKI, Japan, October 15, 2025--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter &quot;PeptiDream&quot;)(Tokyo: 4587), PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, &quot;PDRadiopharma&quot;), a wholly owned subsidiary of PeptiDream, and Curium Group, a world leader in nuclear medicine (CEO: Renaud Dehareng, Headquarters: Boston, Massachusetts, the United States), today announced that a registrational Phase 2</description>
    </item>
  </channel>
</rss>